AR and neoplasm: Galeterone has shown significant anti-tumour activity with a well-tolerated safety profile in patients with CRPC in phase I and II clinical studies [7] including in six out of seven Phase II patients who were identified in a retrospective subset analysis as having truncated AR with C-terminal loss [7].